Janus激酶抑制剂在特应性皮炎治疗中的临床应用研究进展

doi:10.3969/j.issn.1674-8115.2021.07.019

上海交通大学学报(医学版) ›› 2021, Vol. 41 ›› Issue (7): 963-966.doi: 10.3969/j.issn.1674-8115.2021.07.019

• 综述 • 上一篇

Janus激酶抑制剂在特应性皮炎治疗中的临床应用研究进展

庄昊俊(), 郭美亮, 刘婉雯, 邓辉()

上海交通大学附属第六人民医院皮肤科，上海 200233

出版日期:2021-07-28 发布日期:2021-08-03
通讯作者: 邓辉 E-mail:nichijou@sjtu.edu.cn;denghui-1@hotmail.com
作者简介:庄昊俊（1997—），男，硕士生；电子信箱：nichijou@sjtu.edu.cn。
基金资助:
国家自然科学基金(81673054)

Clinical research progress of Janus kinase inhibitors in the treatment of atopic dermatitis

Hao-jun ZHUANG(), Mei-liang GUO, Wan-wen LIU, Hui DENG()

Department of Dermatology, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai 200233, China

Online:2021-07-28 Published:2021-08-03
Contact: Hui DENG E-mail:nichijou@sjtu.edu.cn;denghui-1@hotmail.com
Supported by:
National Natural Science Foundation of China(81673054)

摘要/Abstract

摘要：

特应性皮炎是一种慢性炎症性皮肤病，主要与Th2型信号通路的变化有关。白细胞介素-4（interleukin-4，IL-4）和IL-13的表达增加使聚丝蛋白减少，从而导致皮肤屏障缺陷。Janus激酶-信号转导及转录激活因子（Janus kinase-signal transducer and activator of transcription，Jak-STAT）信号通路与特应性皮炎的发病机制密切相关，抑制Jak-STAT信号通路治疗特应性皮炎是一种有潜力的方法。Janus激酶（Janus kinase，JAK）抑制剂在对JAKs抑制的选择上可分为第一代JAK抑制剂和第二代JAK抑制剂。该综述通过对第一代和第二代JAK抑制剂在临床试验中的疗效和安全性进行总结，阐明JAK抑制剂在特应性皮炎治疗中的临床应用研究进展。

关键词: 特应性皮炎, Jak-STAT信号通路, JAK抑制剂

Abstract:

Atopic dermatitis is a chronic inflammatory skin disease, which is mainly related to changes in Th2 type signaling pathways. Increased expression of interleukin-4 (IL-4) and IL-13 reduces filaggrin, which leads to skin barrier defects. The Janus kinase-singal transducer and activator of transcriprion (Jak-STAT) signaling pathway is closely related to the pathogenesis of atopic dermatitis. Inhibiting the Jak-STAT signaling pathway is a potential method to treat atopic dermatitis. Janus kinase (JAK) inhibitors can be divided into first-generation and second-generation JAK inhibitors in the selection of JAKs′ inhibition. By summarizing the efficacy and safety of the first-generation and second-generation JAK inhibitors in clinical trials, the clinical research progress of JAK inhibitors in the treatment of atopic dermatitis is clarified.

Key words: atopic dermatitis, Jak-STAT signaling pathway, JAK inhibitors

中图分类号:

R751.05

庄昊俊, 郭美亮, 刘婉雯, 邓辉. Janus激酶抑制剂在特应性皮炎治疗中的临床应用研究进展[J]. 上海交通大学学报(医学版), 2021, 41(7): 963-966.

Hao-jun ZHUANG, Mei-liang GUO, Wan-wen LIU, Hui DENG. Clinical research progress of Janus kinase inhibitors in the treatment of atopic dermatitis[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(7): 963-966.

参考文献 25

1	Nutten S. Atopic dermatitis: global epidemiology and risk factors[J]. Ann Nutr Metab, 2015, 66(): 8-16.
2	Avena-Woods C. Overview of atopic dermatitis[J]. Am J Manag Care, 2017, 23(8): S115-S123.
3	Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications[J]. Allergy Asthma Proc, 2019, 40(2): 84-92.
4	Banerjee S, Biehl A, Gadina M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects[J]. Drugs, 2017, 77(5): 521-546.
5	Solimani F, Meier K, Ghoreschi K. Emerging topical and systemic JAK inhibitors in dermatology[J]. Front Immunol, 2019, 10: 2847.
6	Gündüz Ö. JAK/STAT pathway modulation: does it work in dermatology?[J]. Dermatol Ther, 2019, 32(3): e12903.
7	Weidinger S, Novak N. Atopic dermatitis[J]. Lancet, 2016, 387(10023): 1109-1122.
8	Rodrigues MA, Torres T. JAK/STAT inhibitors for the treatment of atopic dermatitis[J]. J Dermatolog Treat, 2020, 31(1): 33-40.
9	王学川, 李霄, 梁承远. 基于JAK-STAT信号通路的药物研究进展[J]. 陕西科技大学学报, 2019, 37(6): 79-86.
10	Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases[J]. Nat Rev Drug Discov, 2017, 17(1): 78.
11	Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream[J]. J Allergy Clin Immunol, 2020, 145(2): 572-582.
12	Bertsias G. Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors[J]. Mediterr J Rheumatol, 2020, 31(): 105-111.
13	Duggan S, Keam SJ. Upadacitinib: first approval[J]. Drugs, 2019, 79(16): 1819-1828.
14	Sonthalia S, Aggarwal P. Oral tofacitinib: contemporary appraisal of its role in dermatology[J]. Indian Dermatol Online J, 2019, 10(5): 503-518.
15	Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase Ⅱa randomized trial[J]. Br J Dermatol, 2016, 175(5): 902-911.
16	Markham A. Baricitinib: first global approval[J]. Drugs, 2017, 77(6): 697-704.
17	Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study[J]. J Am Acad Dermatol, 2019, 80(4): 913-921.e9.
18	Ajayi S, Becker H, Reinhardt H, et al. Ruxolitinib[J]. Recent Results Cancer Res, 2018, 212: 119-132.
19	Dhillon S. Delgocitinib: first approval[J]. Drugs, 2020, 80(6): 609-615.
20	Tanimoto A, Ogawa Y, Oki C, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo[J]. Inflamm Res, 2015, 64(1): 41-51.
21	Nakagawa H, Nemoto O, Igarashi A, et al. Efficacy and safety of topical JTE-052, a janus kinase inhibitor, in japanese adult patients with moderate-to-severe atopic dermatitis: a phase Ⅱ, multicentre, randomized, vehicle-controlled clinical study[J]. Br J Dermatol, 2018, 178(2): 424-432.
22	Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)[J]. BMC Rheumatol, 2018, 2: 23.
23	Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial[J]. J Allergy Clin Immunol, 2020, 145(3): 877-884.
24	Ferreira S, Guttman-Yassky E, Torres T. Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib[J]. Am J Clin Dermatol, 2020, 21(6): 783-798.
25	Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial[J]. JAMA Dermatol, 2020, 156(8): 863-873.

Janus激酶抑制剂在特应性皮炎治疗中的临床应用研究进展

Clinical research progress of Janus kinase inhibitors in the treatment of atopic dermatitis

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 25

相关文章 0

编辑推荐

Metrics